New Harrow (NASDAQ: HROW) CCO granted RSUs tied to revenue

Rhea-AI Filing Summary

Harrow, Inc. filed an update covering its outlook and leadership team. The company reaffirmed its full-year 2025 revenue guidance in a range of $270 million to $280 million, signaling no change to its previously communicated expectations.

Harrow also appointed Patrick W. Sullivan as Chief Commercial Officer, effective January 30, 2026. He brings more than 25 years of commercial leadership experience from roles at Corium Therapeutics, AstraZeneca, Shire, Adolor, Novartis, and Bayer. Under his offer letter, Sullivan will receive a $425,000 annual base salary, a target annual bonus equal to 40% of base compensation, and 40,000 restricted stock units. Of these, 25,000 RSUs vest if Harrow’s revenue reaches $230,000,000 in a calendar quarterly period, and 15,000 RSUs vest three years from the award date.

Insights

Equity analyst focused on healthcare and corporate events

Harrow reaffirms 2025 revenue outlook and adds an experienced commercial leader.

Harrow keeps its full-year 2025 revenue guidance at $270 million to $280 million, indicating management’s confidence in its current business trajectory. This maintains prior expectations rather than introducing new upside or downside in the near term.

The appointment of Patrick W. Sullivan as Chief Commercial Officer adds a leader with extensive commercialization background in neurology, dementia, and anemia therapies. His compensation includes $425,000 base salary, a 40% bonus target, and 40,000 RSUs, aligning part of his upside with Harrow’s performance.

Notably, 25,000 RSUs vest only if revenue reaches $230,000,000 in a calendar quarterly period, while 15,000 RSUs vest after three years from grant. This structure ties a significant portion of equity to both growth and retention, with future filings likely detailing progress against these thresholds.

false 0001360214 0001360214 2026-01-30 2026-01-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 30, 2026

HARROW, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-35814		45-0567010
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1A Burton Hills Blvd., Suite 200
Nashville, Tennessee		37215
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (615) 733-4730

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Stock, $0.001 par value per share		HROW		The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934: Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On February 2, 2026, Harrow, Inc. (the “Company”) issued a press release, which, among other things, reaffirmed the Company’s full-year 2025 revenue guidance of between $270 million and $280 million. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On January 30, 2026, the Company appointed Patrick W. Sullivan, age 50, as Chief Commercial Officer of the Company, effective immediately.

Patrick W. Sullivan joined the Company as Head of Commercial in August 2025, bringing over 25 years of commercial leadership experience. Before joining the Company, Mr. Sullivan was Vice President of Marketing, Neurology Portfolio at Corium Therapeutics, where he led U.S. commercialization and launches in ADHD and dementia. Previously, he served as Global Commercial Head and Executive Director at AstraZeneca, directing the launch of Evrenzo® (roxadustat), a first-in-class anemia therapy. Earlier in his career, he held leadership roles at Shire, Adolor, Novartis, and Bayer. Mr. Sullivan holds a B.S. in Business Administration from Widener University.

There are no arrangements or understandings between Mr. Sullivan and any other person pursuant to which he was selected as officer of the Company.

Mr. Sullivan does not have any family relationships with any director or executive officer of the Company, and there are no related party transactions involving Mr. Sullivan that would require disclosure under Item 404(a) of Regulation S-K.

In connection with Mr. Sullivan’s appointment, the Company entered into an Offer Letter dated January 30, 2026 (the “Offer Letter”), pursuant to which he will receive:

	●	Base Salary of $425,000 per year;
	●	Target annual bonus opportunity of 40% of base compensation, subject to achievement of targets agreed upon; and
	●	40,000 restricted stock units (RSUs): 25,000 RSUs will vest when Harrow’s revenue reaches $230,000,000 in a calendar quarterly period, 15,000 RSUs will vest after 3 years from the date of the award.

The foregoing description of the Offer Letter is qualified in its entirety by reference to the full text of the Offer Letter, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

No.		Description
10.1		Offer Letter dated January 30, 2026 by and between Harrow, Inc and Patrick W. Sullivan
99.1		Press release, dated February 2, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 2, 2026	HARROW, INC.
	By:	/s/ Andrew R. Boll
		Andrew R. Boll
		President and Chief Financial Officer

FAQ

What revenue guidance did Harrow (HROW) reaffirm for full-year 2025?

Harrow reaffirmed full-year 2025 revenue guidance of $270 million to $280 million. This keeps the company’s previously communicated outlook unchanged, suggesting management still expects its current commercial portfolio and plans to support that revenue range for the year.

Who is Harrow’s new Chief Commercial Officer and when was he appointed?

Harrow appointed Patrick W. Sullivan as Chief Commercial Officer, effective January 30, 2026. He joined Harrow as Head of Commercial in August 2025 and brings over 25 years of commercial leadership experience from roles at Corium Therapeutics, AstraZeneca, Shire, Adolor, Novartis, and Bayer.

What are the key compensation terms for Harrow (HROW) CCO Patrick Sullivan?

Patrick Sullivan’s offer includes a $425,000 annual base salary, a target annual bonus of 40% of base compensation, and 40,000 restricted stock units. These terms combine fixed pay, performance-based cash, and equity incentives that link his potential upside to Harrow’s results and long-term commitment.

How do Patrick Sullivan’s restricted stock units (RSUs) at Harrow vest?

Patrick Sullivan receives 40,000 RSUs, with 25,000 RSUs vesting if Harrow’s revenue reaches $230,000,000 in a calendar quarterly period. The remaining 15,000 RSUs vest three years from the award date, creating both performance and time-based incentives for the new Chief Commercial Officer.

Does Harrow’s new CCO Patrick Sullivan have any related-party relationships or family ties at the company?

Harrow states there are no arrangements or understandings with others under which Patrick Sullivan was selected, and he has no family relationships with any director or executive officer. The company also reports no related-party transactions involving him requiring disclosure under Item 404(a) of Regulation S-K.

What exhibits were included with Harrow’s latest 8-K filing?

The filing includes an Offer Letter dated January 30, 2026 between Harrow and Patrick Sullivan as Exhibit 10.1, a press release dated February 2, 2026 as Exhibit 99.1, and the Cover Page Interactive Data File as Exhibit 104 embedded in the Inline XBRL document.